Join
Live feed
·
PRReleasevia Quantisnow
Precigen Inc. logo

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

ByQuantisnow·Wall Street's wire, on your screen.
PGEN· Precigen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PGEN (Precigen Inc.) and more on Quantisnow.